Last week, our colleague Alexandra Wennberg represented Quantify Research at EASL 2026, joining leading researchers, clinicians, and industry experts to discuss the latest advances in liver disease research and patient care.
Several themes stood out across the congress:
• Progress towards a functional cure for hepatitis B, with promising Phase 3 results generating considerable interest
• Continued momentum in MASH, as new evidence further expands treatment possibilities
• Growing recognition of the value of real-world evidence in understanding long-term outcomes and informing healthcare decision-making
• Increasing adoption of precision medicine and data-driven approaches across liver disease research
Beyond the scientific advances, EASL 2026 highlighted the importance of collaboration across stakeholders to ensure that innovation translates into meaningful benefits for patients.
We are grateful for the opportunity to engage with colleagues from across the life sciences community and look forward to applying these insights in our continued work supporting evidence generation and healthcare decision-making.
And for those already planning ahead: we look forward to seeing the hepatology community again when EASL 2027 comes to London.
What development from EASL 2026 do you believe will have the greatest impact on liver disease management over the coming years?
